In cohorts of patients with melanoma and non-small cell lung cancer (NSCLC), acquired resistance often presents as progression at a limited number of sites, implying that local immune or tumor heterogeneity underlies this phenomenon.101,102 Other mechanisms that may contribute to acquired resistance include loss of T-cell function, loss of T-cell tumor recognition and resistance to the effects of IFNγ produced by T-cells.103. Here, IFNG is linked to non-small cell lung carcinoma.